Cardiovascular aspects of ELABELA: A potential diagnostic biomarker and therapeutic target

Vascul Pharmacol. 2023 Jul 9:107193. doi: 10.1016/j.vph.2023.107193. Online ahead of print.ABSTRACTELABELA, an early endogenous ligand for the G protein-coupled receptor APJ (apelin peptide jejunum, apelin receptor), has been known as an important regulator in cardiovascular homeostasis and may be a novel therapeutic target for multiple cardiovascular diseases (CVDs). At the physiological level, ELABELA exhibits angiogenic and vasorelaxant effects and is essential for heart development. At the pathological level, circulating ELABELA levels may be a novel diagnostic biomarker for various CVDs. ELABELA peripherally displays antihypertensive, vascular-protective, and cardioprotective effects, whereas central administration of ELABELA elevated BP and caused cardiovascular remodeling. This review highlights the physiological and pathological roles of ELABELA in the cardiovascular system. Enhancement of the peripheral ELABELA may be a promising pharmacological therapeutic strategy for CVDs.PMID:37433415 | DOI:10.1016/j.vph.2023.107193
Source: Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research